FibroGen, Inc. has provided clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase III program for the treatment of anemia of chronic… read more.
After an appendectomy, a quarter (24.8%) of all children wanted a stronger pain treatment in the first 24 hours after their operation. Among children who had a tonsillectomy,… read more.
Merck Inc., announced that the FDA has issued a Complete Response Letter (CRL) regarding Merck’s supplemental Biologics License Application (sBLA) seeking approval for Keytruda, the company’s anti-PD-1 therapy,… read more.
Roche announced that the European Commission (EC) has approved Evrysdi (risdiplam) for the treatment of 5q spinal muscular atrophy (SMA) in patients two months of age and older,… read more.
As demonstrated by multiple studies over the years, women who breastfeed have a lower risk for developing cardiovascular disease and diabetes when compared to those who don’t or… read more.
Biogen announced that the European Commission (EC) has granted marketing authorization for a subcutaneous (SC) injection of Tysabri (natalizumab) to treat relapsing-remitting multiple sclerosis (MS).
Jazz Pharmaceuticals plc has announced that the FDA approved a revised label for Vyxeos (daunorubicin and cytarabine) to include a new indication to treat newly-diagnosed therapy-related acute myeloid… read more.
Findings from an analysis of the first 500 patients enrolled in the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry) found more than three-quarters (76%) of pulmonary arterial hypertension… read more.
New “sweat stickers” may streamline the early diagnosis of cystic fibrosis by enabling scientists to easily gather and analyze sweat from the skin of infants and children. The… read more.
Abusive alcohol drinking considerably impacts human health. Alcoholism, better defined as Alcohol Use Disorders (AUD), includes a group of pathological entities related to alcohol-induced damage. Individuals with AUD… read more.
Supernus Pharmaceuticals announced that the FDA approved Qelbree (viloxazine extended-release capsules) for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age…. read more.
A Scientific E-Poster to be presented at the 2021 ARRS Virtual Annual Meeting reveals increased rates of emphysema in marijuana smokers, compared to both non-smokers and tobacco-only smokers,… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
